Sorafenib

Overview

Sorafenib is a multi-kinase inhibitor used in the treatment of liver, kidney, and thyroid cancers. It works by inhibiting tumor cell proliferation and angiogenesis.

API suppliers (3)

Suppliers of Sorafenib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MSN Laboratories Private LimitedIndia3 active DMF
• Cipla USA, Inc.USA2 active DMF
• Zhejiang Hisun Pharmaceutical Co., Ltd.China

Patent & exclusivity (US)

Per the FDA Orange Book (6 approved US products), the latest listed US patent on Sorafenib expires 9 Sept 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas